Rubius Therapeutics, Inc. engages in the development of red-cell therapeutic medicines. It provides medicine for cancer, autoimmune diseases, hemophilia, infectious and metabolic diseases. The company was founded on April 26, 2013 and is headquartered in Foxboro, MA.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
N/A
Frequently Asked Questions
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. Rubius Therapeutics Inc market cap is $5.15M.
52 week high is the highest price of a stock in the past 52 weeks, or one year. Rubius Therapeutics Inc 52 week high is $0.3763 as of November 17, 2026.
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Rubius Therapeutics Inc 52 week low is $0.0032 as of November 17, 2026.
Rubius Therapeutics Inc stock price today is $0.057.
Rubius Therapeutics Inc stock price yesterday was $0.0555.
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It's calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company's Market Cap by the Net Profit. Rubius Therapeutics Inc's P/E ratio is -0.03.
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It's calculated by dividing a company's market capitalization by its book value. Rubius Therapeutics Inc P/B ratio is 0.3405.
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. Rubius Therapeutics Inc 50-day moving average is $0.0217.